Nasdaq Biotechnology Ishares ETF (IBB)

$141.30 +1.07 (0.76%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 552,023
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 1-800-474-2737
macrossluvsrobotech
macrossluvsrobotech Jan. 15 at 9:45 PM
$CMPS Will be the first to market. RFK Jr, will unleash this. Topline will be good. Topline in June was EXCELLENT. IT WORKS. All this pending phase 3 comp006 will tell us is dosing. RFK Jr will greenlight this so godamn fast. That event in January, the commercialization. Radial putting in their own money to get the offcices ready. The Hercules Loan, assuring solid 2026-2027 supply of liquidity, with ZERO need for more money. I don't understand why anybody here would even fathom a 6 dollar and change entry here. It's not going to happen. IF YOU WANT TO KNOW WHAT'S GOING TO HAPPEN IN THE NEAR FUTURE UNDE THIS ADMINISTATION? JUST WATCH THE FOLLOWING VIDEO, AND ASK YOURSELF WHO HEADS THE FDA NOW. https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ $ATAI $MNMD $IBB $BIB
0 · Reply
Diefreeandsell
Diefreeandsell Jan. 15 at 8:15 PM
$IBRX $XBI $LABU $TNA $IBB SPEAKING of Volume, I don't think stock has ever had this many days of this kind of elevated volume! VOLUME avg just keep popping up lately! 60.79mil shares, +628% compared to typical volume of 8.35mil by 3:11 pm ET. High Volume alert! Typical daily volume is 10.38mil shares over the past 6 months. Prob get another breakout alert soon!
0 · Reply
QuantLake
QuantLake Jan. 15 at 6:20 AM
Bitcoin Trust surges – Wednesday Daily Snapshot: Top 2 (by %): $IBIT Bitcoin Trust +3.49%, $IBB Biotechnology +0.88% Bottom 2: $MTUM Momentum Factor -1.23%, $IYW US Technology -1.31% Our Perspective: Intermediate-Term momentum/sentiment readout for our Alternatives universe. $IBIT: Bearish Momentum - Negative Sentiment $IBB: Bullish Momentum - Positive Sentiment $MTUM: Bullish Momentum - Neutral Sentiment $IYW: Bullish Momentum - Neutral Sentiment
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 14 at 8:32 PM
$BCRX valuation v. analyst consensus revenue estimates versus Amicus Therapeutics (FOLD). Analysts forecast Amicus' 2 therapies to generate slightly more product sales, but at a slightly lower gross manufacturing margin, than BCRX/Orladeyo over the next 10years. BCRX recently guided to $1B in Orladeyo sales in FY29. Amicus/FOLD is being acquired for $4.8B while BCRX's enterprise value is less than $2B. Orladeyo was first approved in December 2020. It's our experience BCRX (like APLS in our last post) consistently trades at a lower revenue multiple than (non-M&A) peers. Perhaps it is time BCRX consider alternate strategies like M&A to maximize shareholder value. We're only aware of 10 comm'l-stage non-oncology focused bios, of the 170 new such bios since 1/1/13, that generated meaningful value for shareholders by staying independent (and 1 in 61 in oncology). @thehivemindfund This is not investment advice. Of course BCRX's pipeline may generate value, in spite of the odds. $XBI $IBB $NBIS
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 8:19 PM
Enter: $IBB Calls Strike Price: $172 Expiry Date: FEB 20 2026 Buy in Price: $4.00 - $5.60 Sell Price: $7.64 Profit : +91% (Turn every $1 into $1.91) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Eagley3k
Eagley3k Jan. 14 at 8:02 PM
$UNCY feels like a whale is loading. we need to break out of that 3 years down slope line and we are in full reversal mode. $XBI $IBB $IWM
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 6:22 PM
$LXRX Super interesting long term study on Heart, Diabetes growth: THIS IS LITERALLY THE ENTIRE ARTICLE = "A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the burden of disease, quality of care and mortality trends of risk factors and conditions that can lead to heart disease. The study found no change in the prevalence of hypertension among U.S. adults from 2009-2023 but found that hypertension-related cardiovascular deaths nearly doubled from 23 per 100,000 in 2000 to 43 per 100,000 in 2019. The prevalence of diabetes in U.S. adults increased from 11.9% in 2009-2010 to 14.1% in 2021-2023. Deaths related to type 2 diabetes increased from 30.4 per 100,000 adults in 2009 to 54 per 100,000 adults in 2023. The study analyzed other risk factors and conditions such as obesity, cigarette smoking and stroke, among others." https://www.aha.org/news/headline/2026-01-13-study-analyzes-state-us-heart-health-and-risk-factors $VRTS $NVO $IBB $BIB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 14 at 5:24 PM
It appears $APLS is going to do just under $1.0B in FY25 revenues incl just under $700MM in product sales & just over $300MM in licensing. It appears APLS Q425 sales missed ests by ~5%. APLS' shares are down ~25% the last 3 days. The attachment compares APLS 10-year analyst consensus revenue estimates to Amicus $FOLD which is about to be acquired for an enterprise value of roughly $4.8B (market cap of roughly $4.43B as of 1/14/26 per Seeking Alpha). APLS MC = $2.6B & is expected to do more sales @ a slightly lower gross margin FOLD reported $450MM in 9 month product sales trending to ~$600MM for the year. Both sell 2 therapies. It's our experience over the last 2 years APLS usually trades @ lower revenue multiples than peers. APLS trades @ half of FOLD's 10-year M&A revenue multiple. Perhaps FOLD should consider an alternate strategy to maximize shareholder value? Are we wrong? Be careful. For all we know APLS execs may have spooked investors at the JPM HC Conf yesterday. $XBI $IBB $NBI
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:14 PM
$BIB $CMPS $IBB $MNMD $SNDL DEA WOULD BE FORECED TO RECLASSIFY PSILOCYBIN (ONLY THE $CMPS VERSION APPROVED BY THE FDA, IT WOULD NOT BE A GENERAL RECLASSIFICATION) = AFTER FDA APPROVAL AWAY FROM CLASS 1. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $MNMD
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:09 PM
$CMPS $SNDL $CMPS Q1 2026 pending phase 3 topline imminent for COMP 360. I wonder why.. "RUMOR: 🇺🇸 President Trump is considering reclassifying psychedelics as a less harmful drug class." Maybe this is the reason = "COMPASS or others) is the most direct federal route to enabling prescription access. There's also a separate ongoing petition to reschedule psilocybin broadly, advanced by DEA to HHS review in 2025, but that's independent. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $MNMD
0 · Reply
Latest News on IBB
Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground

Jan 14, 2026, 12:23 PM EST - 1 day ago

Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground

BOTZ CHAT SMH SOXX WTAI

Funding for Risky Biotechs Is Returning

Jan 12, 2026, 12:00 PM EST - 3 days ago

Funding for Risky Biotechs Is Returning

XBI

Pharma stocks are set to take off this year, says UBS' Michael Yee

Jan 8, 2026, 11:01 AM EST - 7 days ago

Pharma stocks are set to take off this year, says UBS' Michael Yee

LLY VTYX

Mizuho's Jared Holz on what biotech dealmaking looks like in 2026

Dec 31, 2025, 2:27 PM EST - 15 days ago

Mizuho's Jared Holz on what biotech dealmaking looks like in 2026

XBI

Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

Dec 23, 2025, 2:04 PM EST - 23 days ago

Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus

NVO PPH VHT XBI

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 26 days ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX AZN

3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 6 weeks ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT TVTX XBI CYTK

iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector

Nov 17, 2025, 9:44 AM EST - 2 months ago

iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Nov 14, 2025, 6:17 PM EST - 2 months ago

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

CDTX MRK XBI XLV

'Fast Money' traders talk how to play biopharma space

Nov 11, 2025, 6:56 PM EST - 2 months ago

'Fast Money' traders talk how to play biopharma space

XLV

Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson

Nov 11, 2025, 3:07 PM EST - 2 months ago

Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson

XBI

Investing In Health Stocks - How Policy Clarity Is Opening Doors

Nov 11, 2025, 10:13 AM EST - 2 months ago

Investing In Health Stocks - How Policy Clarity Is Opening Doors

AGNG ARKG BBC BBH BBP BIB BIS

Trade Tracker: Jason Snipe buys the IBB

Oct 17, 2025, 1:30 PM EDT - 3 months ago

Trade Tracker: Jason Snipe buys the IBB

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

‘Fast Money' traders talk opportunities in health care stocks

Oct 1, 2025, 5:48 PM EDT - 3 months ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BIIB BMY LLY MRK MRNA PFE

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Sep 9, 2025, 10:41 AM EDT - 4 months ago

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

XBI

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 4 months ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH BMRN CYTK XBI

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Sep 1, 2025, 8:03 AM EDT - 4 months ago

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Trump's deadline looms for Big Pharma companies facing new tariffs

Jul 16, 2025, 3:30 PM EDT - 6 months ago

Trump's deadline looms for Big Pharma companies facing new tariffs

XLV

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

Jul 13, 2025, 7:01 AM EDT - 6 months ago

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

XLV

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

Jul 9, 2025, 11:09 AM EDT - 6 months ago

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

CPER XBI

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

Jul 6, 2025, 11:12 AM EDT - 6 months ago

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

XBI

5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs

Jul 5, 2025, 8:05 AM EDT - 6 months ago

5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs

ACHC AMH ARE CHAT COLD ELS FSLR

Fast Money: WTI, IBB, UBER, CAT

Jun 13, 2025, 6:20 PM EDT - 7 months ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT

Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 8 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIB BIS

IBB: Now Is The Time To Be Contrarian

May 29, 2025, 10:59 AM EDT - 8 months ago

IBB: Now Is The Time To Be Contrarian

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 8 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD ILMN NVS SDGR

Trump is right about drug prices. He's just going about it all wrong.

May 13, 2025, 1:43 PM EDT - 8 months ago

Trump is right about drug prices. He's just going about it all wrong.

XBI XLV

New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 9 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI

Trump Says Pharmaceutical Tariffs Coming in Near Future

Apr 14, 2025, 2:03 PM EDT - 9 months ago

Trump Says Pharmaceutical Tariffs Coming in Near Future

ABBV AMGN AZN BMY GSK JNJ LLY

Sell into strength in pharma, says Mizuho's Jared Holz

Apr 11, 2025, 7:17 PM EDT - 9 months ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

Apr 11, 2025, 10:30 AM EDT - 9 months ago

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

ABBV AMGN AZN BMY GSK JNJ LLY

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Apr 11, 2025, 5:30 AM EDT - 9 months ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

XBI

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

Apr 9, 2025, 6:32 PM EDT - 10 months ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

ABBV AMGN AZN BMY GSK JNJ LLY

Explainer: Prescription drugs become a target in Trump's trade war

Apr 9, 2025, 2:27 PM EDT - 10 months ago

Explainer: Prescription drugs become a target in Trump's trade war

ABBV AMGN AZN BMY GSK JNJ LLY

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

Apr 9, 2025, 1:06 PM EDT - 10 months ago

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

ABBV AMGN AZN BMY GSK JNJ LLY

Why drug stocks are no longer a safe haven from the stock market's turmoil

Apr 9, 2025, 11:49 AM EDT - 10 months ago

Why drug stocks are no longer a safe haven from the stock market's turmoil

ABBV AMGN BMY JNJ LLY MRK PFE

Invest In A New Biotech Bull Market With XBI And IBB

Mar 2, 2025, 8:33 AM EST - 11 months ago

Invest In A New Biotech Bull Market With XBI And IBB

XBI

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 11 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

XLV AGNG ARKG BBC BBH BBP BIB

How tariffs could impact pharma and early-stage healthcare investments

Feb 3, 2025, 6:43 PM EST - 1 year ago

How tariffs could impact pharma and early-stage healthcare investments

XLV

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH ELVN

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 1 year ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

iShares Biotechnology ETF: Playing Defense

Dec 10, 2024, 1:33 PM EST - 1 year ago

iShares Biotechnology ETF: Playing Defense

Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation

Nov 25, 2024, 6:44 PM EST - 1 year ago

Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation

HIMS LLY MRNA NVO PFE

Health care stocks jump on Trump's nominee for FDA head

Nov 25, 2024, 6:22 PM EST - 1 year ago

Health care stocks jump on Trump's nominee for FDA head

HIMS LFMD MRNA PFE

Final Trade: Euro, IBB, SMH, NEM

Nov 20, 2024, 6:21 PM EST - 1 year ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM

Final Trade: West Pharma, Cameco, iShares Biotechnology ETF and Applied Digital Corp

Nov 15, 2024, 6:54 PM EST - 1 year ago

Final Trade: West Pharma, Cameco, iShares Biotechnology ETF and Applied Digital Corp

APLD CCJ WST

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

Oct 14, 2024, 7:36 AM EDT - 1 year ago

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Aug 30, 2024, 5:34 PM EDT - 1 year ago

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

GILD XBI

macrossluvsrobotech
macrossluvsrobotech Jan. 15 at 9:45 PM
$CMPS Will be the first to market. RFK Jr, will unleash this. Topline will be good. Topline in June was EXCELLENT. IT WORKS. All this pending phase 3 comp006 will tell us is dosing. RFK Jr will greenlight this so godamn fast. That event in January, the commercialization. Radial putting in their own money to get the offcices ready. The Hercules Loan, assuring solid 2026-2027 supply of liquidity, with ZERO need for more money. I don't understand why anybody here would even fathom a 6 dollar and change entry here. It's not going to happen. IF YOU WANT TO KNOW WHAT'S GOING TO HAPPEN IN THE NEAR FUTURE UNDE THIS ADMINISTATION? JUST WATCH THE FOLLOWING VIDEO, AND ASK YOURSELF WHO HEADS THE FDA NOW. https://youtu.be/4V7C_bdsu1Q?si=rpOD-fRVVLWvZcOJ $ATAI $MNMD $IBB $BIB
0 · Reply
Diefreeandsell
Diefreeandsell Jan. 15 at 8:15 PM
$IBRX $XBI $LABU $TNA $IBB SPEAKING of Volume, I don't think stock has ever had this many days of this kind of elevated volume! VOLUME avg just keep popping up lately! 60.79mil shares, +628% compared to typical volume of 8.35mil by 3:11 pm ET. High Volume alert! Typical daily volume is 10.38mil shares over the past 6 months. Prob get another breakout alert soon!
0 · Reply
QuantLake
QuantLake Jan. 15 at 6:20 AM
Bitcoin Trust surges – Wednesday Daily Snapshot: Top 2 (by %): $IBIT Bitcoin Trust +3.49%, $IBB Biotechnology +0.88% Bottom 2: $MTUM Momentum Factor -1.23%, $IYW US Technology -1.31% Our Perspective: Intermediate-Term momentum/sentiment readout for our Alternatives universe. $IBIT: Bearish Momentum - Negative Sentiment $IBB: Bullish Momentum - Positive Sentiment $MTUM: Bullish Momentum - Neutral Sentiment $IYW: Bullish Momentum - Neutral Sentiment
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 14 at 8:32 PM
$BCRX valuation v. analyst consensus revenue estimates versus Amicus Therapeutics (FOLD). Analysts forecast Amicus' 2 therapies to generate slightly more product sales, but at a slightly lower gross manufacturing margin, than BCRX/Orladeyo over the next 10years. BCRX recently guided to $1B in Orladeyo sales in FY29. Amicus/FOLD is being acquired for $4.8B while BCRX's enterprise value is less than $2B. Orladeyo was first approved in December 2020. It's our experience BCRX (like APLS in our last post) consistently trades at a lower revenue multiple than (non-M&A) peers. Perhaps it is time BCRX consider alternate strategies like M&A to maximize shareholder value. We're only aware of 10 comm'l-stage non-oncology focused bios, of the 170 new such bios since 1/1/13, that generated meaningful value for shareholders by staying independent (and 1 in 61 in oncology). @thehivemindfund This is not investment advice. Of course BCRX's pipeline may generate value, in spite of the odds. $XBI $IBB $NBIS
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 14 at 8:19 PM
Enter: $IBB Calls Strike Price: $172 Expiry Date: FEB 20 2026 Buy in Price: $4.00 - $5.60 Sell Price: $7.64 Profit : +91% (Turn every $1 into $1.91) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Eagley3k
Eagley3k Jan. 14 at 8:02 PM
$UNCY feels like a whale is loading. we need to break out of that 3 years down slope line and we are in full reversal mode. $XBI $IBB $IWM
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 6:22 PM
$LXRX Super interesting long term study on Heart, Diabetes growth: THIS IS LITERALLY THE ENTIRE ARTICLE = "A study released Jan. 12 by the Journal of the American College of Cardiology analyzed the current state of heart health in the U.S., highlighting the burden of disease, quality of care and mortality trends of risk factors and conditions that can lead to heart disease. The study found no change in the prevalence of hypertension among U.S. adults from 2009-2023 but found that hypertension-related cardiovascular deaths nearly doubled from 23 per 100,000 in 2000 to 43 per 100,000 in 2019. The prevalence of diabetes in U.S. adults increased from 11.9% in 2009-2010 to 14.1% in 2021-2023. Deaths related to type 2 diabetes increased from 30.4 per 100,000 adults in 2009 to 54 per 100,000 adults in 2023. The study analyzed other risk factors and conditions such as obesity, cigarette smoking and stroke, among others." https://www.aha.org/news/headline/2026-01-13-study-analyzes-state-us-heart-health-and-risk-factors $VRTS $NVO $IBB $BIB
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 14 at 5:24 PM
It appears $APLS is going to do just under $1.0B in FY25 revenues incl just under $700MM in product sales & just over $300MM in licensing. It appears APLS Q425 sales missed ests by ~5%. APLS' shares are down ~25% the last 3 days. The attachment compares APLS 10-year analyst consensus revenue estimates to Amicus $FOLD which is about to be acquired for an enterprise value of roughly $4.8B (market cap of roughly $4.43B as of 1/14/26 per Seeking Alpha). APLS MC = $2.6B & is expected to do more sales @ a slightly lower gross margin FOLD reported $450MM in 9 month product sales trending to ~$600MM for the year. Both sell 2 therapies. It's our experience over the last 2 years APLS usually trades @ lower revenue multiples than peers. APLS trades @ half of FOLD's 10-year M&A revenue multiple. Perhaps FOLD should consider an alternate strategy to maximize shareholder value? Are we wrong? Be careful. For all we know APLS execs may have spooked investors at the JPM HC Conf yesterday. $XBI $IBB $NBI
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:14 PM
$BIB $CMPS $IBB $MNMD $SNDL DEA WOULD BE FORECED TO RECLASSIFY PSILOCYBIN (ONLY THE $CMPS VERSION APPROVED BY THE FDA, IT WOULD NOT BE A GENERAL RECLASSIFICATION) = AFTER FDA APPROVAL AWAY FROM CLASS 1. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $MNMD
1 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 5:09 PM
$CMPS $SNDL $CMPS Q1 2026 pending phase 3 topline imminent for COMP 360. I wonder why.. "RUMOR: 🇺🇸 President Trump is considering reclassifying psychedelics as a less harmful drug class." Maybe this is the reason = "COMPASS or others) is the most direct federal route to enabling prescription access. There's also a separate ongoing petition to reschedule psilocybin broadly, advanced by DEA to HHS review in 2025, but that's independent. In short, successful COMP006 data → positive Phase 3 program → FDA approval would force DEA to reschedule the COMP360 product, enabling legal medical use federally. This aligns with the same evidence-based CSA criteria used for marijuana's ongoing review, but through a different mechanism. https://x.com/coinvo/status/2011336228478533873?s=46 $IBB $BIB $MNMD
0 · Reply
scorpiess10
scorpiess10 Jan. 14 at 4:31 PM
$IBRX $XBI $IWM $IBB $VBK
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 14 at 4:25 PM
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval $IBRX $XBI $IWM $IBB $VBK https://stocktwits.com/news/equity/markets/why-did-ibrx-stock-gain-retail-attention-today/cmULjP5R4eA
1 · Reply
OceanThunder7
OceanThunder7 Jan. 14 at 3:31 PM
$IVVD 3000 put contracts at 2.50 expire Friday! Put writers know we are going higher. $IBB $QQQ
1 · Reply
JFais
JFais Jan. 14 at 2:48 PM
$XBI $IBB 5-year survival rate across all cancers has reached 70% (per American Cancer Society report) vs 50% when the National Cancer Act was passed in 1971! Will get even better with all the progress biotech is currently making (ie. $RVMD in pancreatic!) (Hat tip to Premie)
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 14 at 12:39 PM
Why Did NRXP Stock Surge 21% Pre-Market Today? $NRXP $IBB $XBI $PPH $IHE https://stocktwits.com/news/equity/markets/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL
0 · Reply
JFais
JFais Jan. 14 at 12:50 AM
$XBI $IBB Quite a few stocks out there in bioland that ppl are high on, that had a fantastic 2025 But may take a year+ to settle into current valuation (be prepared for a stagnant 2026 in such names) Have to ask yourself at CURRENT valuation, what moves the needle from here?
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:18 AM
$SNDL Dumb ass shorts posting dumb shit, one little bible thumper study, & he thinks it nullifies an Executive order, no son... your stupid... @Slickerthanall187, and the dumbass puts, shorts shares borrowed, or sold calls... also stupid, every day that passes brings us closer to class 3, super smart guy. ALL THE STUDIES A BREAK DOWN OF OVER 250 STUIDIES , I just posted 1 of them below, the breast cancer 1 , SEE SCREEN SHOT = "2025 Cannabis Research: A Breakdown of Over 250 Studies" "The pace of cannabis research in 2025 has been unprecedented. Through the end of August, scientists around the world have released hundreds of peer-reviewed studies exploring nearly every facet of the plant and its compounds." https://themarijuanaherald.com/2025/08/2025-cannabis-research-a-breakdown-of-over-250-studies/ CATCHING THE WHITE HOUSES ATTENTION, TO RESCHEDULE IT TO CLASS 3 = https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ FDA PENDING APPROVAL OF PSILOCYBIN TREATMENT FOR VETERANS AND OTHER NEURO DIVERGENT SUFFERING INDIVIDUALS IS ONE EXAMPLE . https://youtu.be/4V7C_bdsu1Q?si=c3DLCfr911aYdoYe $IBB $BIB $TLRY $JNJ
0 · Reply
crainiac
crainiac Jan. 14 at 12:14 AM
$LABU $IBB $XBI Big Pharma, Big Tech Collaborate on Physical AI Drug Development NVIDIA, Eli Lilly Launch $1B Institute for 24/7 AI-Driven Drug Development https://www.chosun.com/english/industry-en/2026/01/14/UEZUKIUIE5GCPM67HMZQM2ETWM/
0 · Reply
crainiac
crainiac Jan. 14 at 12:13 AM
$LABU $IBB $XBI Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz Artificial intelligence is moving quickly into drug discovery as pharmaceutical and biotech companies look for ways to cut years off R&D timelines and increase the chances of success amid rising costs. More than 200 startups are now competing to weave AI directly into research workflows, attracting growing interest from investors. Converge Bio is the latest company to ride that shift, securing new capital as competition in the AI-driven drug discovery space heats up. https://techcrunch.com/2026/01/13/ai-drug-discovery-startup-converge-bio-pulls-in-25m-from-bessemer-and-execs-from-meta-openai-and-wiz/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:13 AM
$SNDL ALL THE STUDIES A BREAK DOWN OF OVER 250 STUIDIES , I just posted ONE of them below, the breast cancer one , SEE SCREEN SHOT = "2025 Cannabis Research: A Breakdown of Over 250 Studies" "The pace of cannabis research in 2025 has been unprecedented. Through the end of August, scientists around the world have released hundreds of peer-reviewed studies exploring nearly every facet of the plant and its compounds." Aug 2025 https://themarijuanaherald.com/2025/08/2025-cannabis-research-a-breakdown-of-over-250-studies/ CATCHING THE WHITE HOUSES ATTENTION, TO RESCHEDULE IT TO CLASS 3 = https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/ FDA PENDING APPROVAL OF PSILOCYBIN TREATMENT FOR VETERANS AND OTHER NEURO DIVERGENT SUFFERING INDIVIDUALS IS ONE EXAMPLE . https://youtu.be/4V7C_bdsu1Q?si=c3DLCfr911aYdoYe $IBB $BIB $TLRY $JNJ
0 · Reply
crainiac
crainiac Jan. 14 at 12:11 AM
$LABU $IBB $XBI DCVC, NVIDIA Back Proxima’s US$80 Million Bet on AI Drug Discovery https://investingnews.com/nvidia-invests-proxima-ai-drugs/
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Jan. 14 at 12:06 AM
$SNDL Just one of TONS OF STUDIES ON BENEFITS= "Nanoparticle Delivery of CBD Shows Strong Tumor Inhibition in Triple-Negative Breast Cancer By Anthony Martinelli in News, Studies A study published today by Oxford Academic’s Journal of Pharmacy and Pharmacology finds that cannabidiol (CBD), when delivered through a folic acid-modified chitosan (FA-CS) nanoparticle system, significantly inhibited tumor growth in triple-negative breast cancer (TNBC), an aggressive form of the disease with few effective treatment options." Aug 2025 https://themarijuanaherald.com/2025/08/nanoparticle-delivery-of-cbd-shows-strong-tumor-inhibition-in-triple-negative-breast-cancer/ $TLRY $IBB $GILD $CURLF
0 · Reply